This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk06: Good morning. I'll be your conference operator today. At this time, I would like to welcome everyone to the New Lake Capital fourth quarter and full year 2021 earnings conference call. Today's call is being recorded. I will now turn the call over to Walter Pinto, Managing Director of KCSA Strategic Communications. Please go ahead.
spk03: Thank you, Operator. Good morning and welcome everyone to the New Lake Capital Partners fourth quarter and full year 2021 earnings conference call. I'm joined today by David Weinstein, Chief Executive Officer, Anthony Coniglio, President and Chief Investment Officer, Fred Starker, Chief Financial Officer, and Jared Annenberg, Director of Acquisitions. Before we begin, I'm going to remind everyone that statements made during today's conference call may be deemed forward-looking statements with the meaning of the safe harbor of the Private Securities Litigation Reform Act of 1995, and actual results may differ materially due to a variety of risks and uncertainties and other factors. For a detailed discussion of the risks and uncertainties of the company's business, I refer you to the press release issued this morning and filed with the SEC on Form 8K, as well as the company's 10K and other reports filed periodically with the SEC. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. With that, it's my pleasure to turn the call over to Mr. David Weinstein.
spk00: David, please go ahead. Thank you, Walter, and thank you again, everyone, for joining our call. 2021 was a transformative year for New Lake. During the first quarter of 2021, we completed our merger of New Lake and Green Acreage, raising over $100 million in connection with that event. Five months later, in August of 2021, we successfully closed on our initial public offering, raising another $100 million in gross proceeds. Over the entirety of 2021, our team has worked diligently to build relationships, source transactions, and invest our capital in strategic cannabis real estate with high-quality tenants. While we are proud of our growth, we are keenly focused on quality, not quantity. Our long-term success will be built upon the discipline we continue to exercise when making investment decisions. Our model is quite simple. We want to create long-term partnerships with the highest quality cannabis operators, that are strategically located in limited licensed states and jurisdictions throughout the United States. While we do not expect to announce a transaction every week or every month for that matter, the focus of our strategy is long-term ROI for our shareholders. As of December 31st, our portfolio had a 14.5-year weighted average lease term, a 12.5% weighted average yield, and built-in growth through unfunded tenant improvements, and lease escalators. This built-in growth, combined with our ability to continually invest capital, has allowed us to increase our dividend each quarter since going public. Our conviction in the growth of the business remains strong. The cannabis industry is still in the early innings, expected to grow to $46 billion by 2026 from $24 billion in 2021. Operators will need to continue to access capital to fuel this growth. Today, our portfolio is comprised of 28 properties across 11 states, totaling 1.4 million square feet, 90% of which are cultivation facilities and 10% of which are dispensaries. Our nine tenants include premier cannabis operators, both public companies such as Cureleaf, Cresco, Trulieve, and ColumbiaCare, and private companies such as Organic Remedies, Mint, and Revolutionary Clinics. We also have provided one mortgage loan collateralized by a cultivation facility. Our financial performance reflects the quality of our strategy and portfolio. We recently announced a first quarter dividend of 33 cents per share, or $1.32 annualized, and our long-term expected target AFFO payout ratio is 80 to 90%. As a reminder, Aside from $2 million of outstanding seller financing related to our organic remedies acquisition, we currently have no outstanding debt. We are actively pursuing, with a number of lenders, debt capital to fund additional acquisitions. While there is no guarantee that we will be able to raise this capital, we are optimistic given the current ongoing discussions. We are currently in negotiation on a number of transactions and will provide more details on these and any debt capital as these situations progress. Finally, I'd like to address certain dynamics relating to trading in cannabis-related stocks. It has become more challenging for investors to trade in these stocks as certain banks have restricted secondary trading of cannabis-related stocks that do not trade on either the New York Stock Exchange or NASDAQ. We believe that this has created a less than optimal trading volume and liquidity in all OTC-traded cannabis-related stocks, including ours. We have been evaluating alternatives to uplist to a major exchange such as NASDAQ. We are currently engaged with NASDAQ regarding a potential approach for an uplist, but there is no certainty that we will ultimately receive approval. It is premature for us to say much more other than we understand that this is an important issue for our company and our shareholders, and we are very focused on working through this issue. I'd now like to turn the call over to Anthony to discuss our investment portfolio in more detail. Anthony?
spk01: Thanks, David, and thanks again, everybody, for joining our call, and happy St. Patrick's Day. Today, I plan to cover our Q4 acquisitions. I'll review our overall portfolio and then provide some commentary around the pipeline. In the fourth quarter, we successfully closed on two transactions. In November, We provided Hero Diversified Associates with a $30 million nine month senior secured loan. We uniquely structured the loan to convert to a 20 year sale lease back unless a specific provision in the loan agreement is satisfied by July 29th of this year. This transaction really is a great testament to the creativity of our team in structuring a transaction to meet the client's needs. While we can't predict the future, we do expect this transaction to convert to a 20 year sale lease back upon that expiration of July 29th. In December, we announced the closing on the purchase of a 70,000 square foot industrial property in Missouri, and we entered into a 17-year triple net lease with Organic Remedies. The total investment in the property will be $21.1 million, which included $16.1 million at closing and a commitment to fund $5 million of tenant improvement allowances, I would say $3.2 million of which we've funded to date. We're excited to be partnering with the team at Organic Remedies. In part, that team is led by founders of Pure Pen, who we've known since 2019 when we provided them a sale-leaseback transaction on their Pennsylvania facility. Pure Pen, some of you may recall, sold to Trulieve last year, and the management team is now partnered with Organic Remedies on this vertically integrated Missouri business. Turning to a discussion of our overall portfolio, We're very happy with the health of the portfolio and the outlook for our tenants. To remind you, we have some of the leading operators in the cannabis industry, from large multi-state operators to best-in-class single-state operators. Based on most recent reporting, all but one of our tenants is adjusted EBITDA positive, and that one tenant is expected to achieve that important milestone for cannabis operators during the first half of 2022. Our focus on underwriting based on tenant quality, the cannabis market, the licensing, and the real estate has really served us well. And we've been collecting 100% of rent due with no abatements or deferrals since inception. And our underwriting approach continues to provide a solid foundation for future investment decisions. As you know, we monitor our tenants diligently, and we continue to have confidence in the portfolio's performance. Let's have a quick look at our top five tenant financial results for the fourth quarter or most recently reported period. Our largest tenant, Curaleaf, where we own 10 dispensaries across six limited licensed states and one cultivation facility in Florida, posted Q4 revenue of $320 million and adjusted EBITDA of $80 million, resulting in full year 2021 revenue of $1.2 billion, and full year 2021 adjusted EBITDA of $298 million. With 117 dispensaries and a sizable wholesale business, we believe Cureleaf is positioned to continue scaling across its 23 state footprint. Our second largest tenant, Cresco, where we own their largest cultivation facility in Illinois, will report Q4 earnings next week. Industry analysts expect Cresco to build upon its record third quarter results, and potentially see continued margin expansion and revenue growth in their Q4 results as the company added scale via M&A in Pennsylvania and Massachusetts. I would note that adult use sales in Illinois, where Cresco is the top-selling brand and our property is located, that those sales more than doubled in 2021 versus 2020, which was the inaugural year of adult use sales in Illinois and is proving to be the sizable market we all expected it to be. Our third largest tenant is Revolutionary Clinics. It's a vertically integrated platform with three dispensaries in the Boston metro area, and we own their cultivation facility in Fitchburg, Massachusetts. While the company is private and we can't share financial information, we can tell you that we continue to be very comfortable with the credit risk profile of this tenant. Trulieve, our fourth largest tenant, where we own a Pennsylvania cultivation facility, will report fourth quarter results at the end of March. But Q3 results delivered $98 million of adjusted EBITDA on an industry-leading 67% gross margin. Trulieve has been demonstrating an ability to expand their margin in their home market of Florida, all while they've seen increased competition. Integration of the harvest acquisition should add further scale and diversification of their business, and we look forward to seeing their results. Rounding out our top five tenants is ColumbiaCare. We own five of their facilities, three dispensaries, and two cultivation facilities. ColumbiaCare reports next week but announced preliminary results for the full year 2021, which disclosed over $470 million of revenue and $85 million of adjusted EBITDA. The company has a strong footprint in large, limited license markets, which should bode well for its long-term success. Lastly, some comments on our pipeline. Since inception, we've reviewed over $4 billion of sale-leaseback transactions, resulting in a $338 million committed capital. Our pipeline in the fourth quarter was robust. However, as David properly articulated, quality is of the utmost importance. This is indeed a chunky business serving a highly regulated industry, and transaction timelines don't always line up nicely with quarterly earnings calls. We continue to see a steady flow of opportunities as the industry focuses on raising non-dilutive capital while equity valuations are depressed and a rising rate environment makes death less attractive for many market participants. Our focus is on quality and we'll be patient in sourcing the right transactions. Having said that, we continue to have confidence that we will deploy our available capital within six to nine months from our IPO which takes us through the May period. With that, I'll hand it over to our CFO, Fred Starker, to walk through our financial results in more detail. Fred, over to you.
spk08: Thanks, Anthony. Good morning, everyone. Our rental income for the three months ended December 31, 2021, increased by approximately $4.3 million to approximately $8.4 million. compared to approximately $4.1 million for the three months ended December 31, 2020. Rental income for the 12 months ended December 31, 2021, increased by approximately $15.9 million to approximately $27.6 million, compared to $11.7 million for the 12 months ended December 31, 2020. The increases in rental income were significantly impacted by the 19 properties acquired in March 2021 in connection with the merger. Net income attributable to common shareholders for the three months ended December 31st, 2021 increased to 4.3 million as compared to a net income attributable to common shareholders of 2.9 million for the same period in 2020. Net income attributable to common shareholders for the 12 months ended December 31st, 2021 increased to 11.2 million as compared to a net loss attributable to common shareholders of 10.7 million for the same period in 2020. The 2020 net loss was attributable to the internalization of our external manager in July 2020. Our general administrative expenses for the three months ended December 31st, 2021 increased by approximately $1.1 million to approximately $1.9 million as compared to approximately $800,000 for the three months ended December 31st, 2020. For the 12 months ended December 31st, 2021, our G&A expense increased by approximately $2.3 million to approximately $6.4 million as compared to $4.1 million for the 12 months ended December 31, 2020. It's important to note that the increase in our G&A expense was significantly impacted by non-recurring OJRA and public company expenses. Going forward, we anticipate recurring general administrative expenses to be around $7 million for the year. For the fourth quarter of 2021, AFFO attributable to common shareholders was approximately 7 million. For the 12 months of 2021, AFFO attributable to common shareholders was approximately 21 million. In mid-December, we declared a fourth quarter 2021 cash dividend of 31 cents per share, equivalent to an annualized dividend of $1.24. as compared to our third quarter annualized dividend of 96 cents. On March 15th, we declared a first quarter 2022 cash dividend of 33 cents per share, equivalent to an annualized dividend of $1.32. Note that FFO and AFFO are supplemental non-GAAP financial measures used in the real estate industry to measure and compare the operating performance of real estate companies. A complete reconciliation containing adjustments from GAAP, net income, attributable to common shareholders to FFO and ASFO, and definitions of terms are included at the end of our press release. Please refer to that press release for more information. With that, I will turn it back over to David for closing remarks.
spk00: Thank you, Fred. And again, thank you all for joining us this morning. In closing, I'm proud of what our team has accomplished in a rather short period. Given the trajectory of the cannabis industry and our growing pipeline, we expect to continue to execute and grow while exercising a continued discipline approach. I would now like to open up the call for questions. Operator? Thank you.
spk06: We will now be conducting the question and answer session. If you'd like to ask a question, please press star 1 from your telephone keypad and a confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants that are using speaker equipment, it may be necessary to pick up your handset before pressing the star keys.
spk07: One moment, please, while we poll for questions. Thank you. Our first question comes from the line of John Misosha with Ladenburg Salmon. Please receive your questions. Good morning. Morning, John.
spk05: So I've got to start with your comments on uplifting, even though I know you might not be able to talk too much on it. Is the barrier to listing on NASDAQ at this time just the structure of your ownership interest in the properties in the portfolio? NASDAQ is clearly comfortable with mortgage rates listing on the exchange. So is it just really being driven by your direct equity position in the real estate?
spk07: That's the primary focus, yes.
spk05: Okay, so there's nothing else that would need to be kind of changed in terms of the portfolio in order to get that comfortable with the listing?
spk01: Yeah, John, we've always run the company to qualify for listing on a New York or a NASDAQ, and the only thing that precludes us is that ownership, that legal ownership of the properties at this time.
spk05: Okay. And switching gears a little bit, I mean, how does the pipeline look today? Are you still kind of thinking about, you know, nine months as the timeline to deploy the IPO capital that was raised? Or is it just, you know, because of different market dynamics, you know, macroeconomic volatility is going to take a little more time to kind of deploy all of that capital?
spk01: Yeah, I'm going to hand it off to Jared. I'd say from – this is Anthony. I'll hand it off to Jared. From a macro perspective – As I said in the prepared remarks, we feel confident that we'll be able to fulfill the promise that we made to investors when we were launching the IPO and raising our capital, that we would be fully deployed in six to nine months. That takes us through the May period. But, Jarrett, why don't you give a flavor for what we're seeing in the pipeline?
spk04: Yeah, absolutely. Thanks, Anthony. So from our perspective, the pipeline remains as robust as really it has been since inception. And we're active in negotiations with operators, discussions with operators across the country. As David noted, the sales cycle in this business is chunky and unpredictable. Really, it ebbs and flows with the cannabis market overall. But we see a tremendous demand for our capital. I think as Anthony said, we'll continue with that guidance in the next nine months from the IPO. But we also need to be diligent as we maintain our focus on seeking out transactions with quality operators in limited license jurisdictions.
spk05: Okay. And maybe as a follow-up, I mean, how important to maybe your TAM or even the pipeline directly is kind of the rollout of adult use programs in some of these larger northeastern states, you know, New York, Connecticut, New Jersey, et cetera?
spk04: Yeah, as you can imagine, we're having a conversation with the operators in those states. As those programs roll out, I do think that most of those operators want to get ahead of those markets and are starting to think about expansion long before those programs are implemented. But we see opportunities in those markets as well as markets like Missouri where we expect medical to turn into adult use, Maryland where we expect the same thing, and then some new states that are coming online like Georgia, Mississippi, which has turned online as well.
spk05: And then one last one. On kind of the debt side of things, you mentioned it's still an attractive place for you to raise capital. How has pricing trended there, just given maybe some of the macro and economic uncertainty and interest rate uncertainty that's out there? But obviously, any transaction with you would be fairly bespoke, given what you own and just kind of your unique position in the REIT market.
spk00: Yeah, John, this is David. I would say, first of all, we have no debt, essentially. And we also have a great portfolio, so it's not that challenging for us to get that. I think we'd probably end up in mid-single digits.
spk07: Okay. That's all for me. Thank you all very much. Thank you, John. Thank you.
spk06: As a reminder, you may press star 1 to ask a question. The next question is from the line of Meryl Ross with CompassPoint. Please proceed with your questions.
spk02: Good morning. Thank you. On the HERO diversified loan, are the terms of the sale we spec significantly different than the terms of the loan? I would assume the loan is smaller than the proceeds from the sale of the property, but what kind of yield is on that instrument when it converts?
spk01: Yes, the transaction size doesn't change. It's an extension of the term, not extension, it switches into a sale lease back. So it becomes a 20-year sale lease back. But the yield doesn't change. It's not a whole new transaction. It really, that triggering event allows us to then purchase the building and enter into that long-term lease, which has already been negotiated and signed and in place as part of that conversion.
spk00: Merrill, you should think of that transaction as it was structured
spk01: a loan form similar to a sale lease back from the beginning with the anticipation that it would convert to a sale lease back so the conversion happens completion of occupancy certificate or occupancy or what it's not occupancy we can't disclose what the trigger event is but what we can say Merrill is that we do feel good about that the transaction will convert to a sale lease back on July 29th. But listen, there are no guarantees, and perhaps it gets repaid. If it does get repaid, then there's, when you look at the totality of the yield on that transaction with the exit fee, we're going to feel really good about the return on having deployed that capital for the nine-month period.
spk02: And I have an unrelated question. Are you seeing at the retail level price pressures or pricing wars on the cannabis product that would maybe lessen your tenant's profitability? I know we're seeing it in California, and I just want to see, you know, hear from you if there's similar supply dynamics in any of the limited licensed states.
spk01: For sure, Jarrett. Why don't you give a sense for what we're seeing at the retail level?
spk04: Yeah, I think that the East State is obviously a very different market and a unique market. As we see, you know, in a state like Massachusetts, as more operators bring cultivation space online, you're starting to see price compression, which obviously trickles down to the retail level. In Florida, you're seeing the same as groups bring on additional cultivation space. Cureleaf, in particular, cut into true leaf margins in Florida by lowering pricing in But we've built that into our models. I think we've always been very conservative in our underwriting, and we've expected compression in the limited-license states as additional cultivation has been brought online. But it's really nothing like what you see in California, where it's an unlimited-license state.
spk01: And I would add, Merrill, that specifically with respect to retail, when you get below, say, $5 million, you actually see a fairly strong bid for – you see a fairly strong bid from, say, 1031 buyers that are willing to go to a cap rate that just isn't attractive for our business.
spk02: I understand that. Thank you.
spk07: Thank you. As a reminder, you may press star 1 to ask a question. Thank you. At this time, there are no additional questions. I'll turn the floor back to management for further remarks.
spk00: All right, well, thank you, everyone, for joining, and we look forward to the future. We're very confident, as I said, in the growth of the business. So take care, everyone.
spk06: This will conclude today's conference.
spk00: Let me disconnect your lines at this time. Thank you for your participation.
Disclaimer